IL34 and carcinoma: It was also shown that expression of IL-34 was more pronounced in patients not responsive to neoadjuvant chemotherapy than in those who were responsive, and patients with cancers expressing high levels of IL-34 had worse prognoses as compared with patients with IL34-low carcinoma [69].